TickerTain — Make Analysis Fun Again

▶ 13:27 · $CRISPR · Doudna says in-vivo delivery is the next unlock for CRISPR therapies

now playing · $CRISPR

$CRISPR···bullish· mediumjennifer doudna

Doudna says the CRISPR startup ecosystem has already spun out 31 companies worth $9B

The investment signal is not a single ticker but the scale of the CRISPR commercialization pipeline: dozens of companies, thousands of jobs, and continued progress toward real-wor…

$OPENAIbearish· mediumjennifer doudna

Jennifer Doudna pushes back on OpenAI-style claims that chatbots will own drug discovery

Doudna says AI can help summarize data and improve discovery efficiency, but she does not see chatbots inventing new drug ideas or justifying a claim on future drug sales today.

$CRISPR···bullish· mediumjennifer doudna

Doudna says in-vivo delivery is the next unlock for CRISPR therapies

Doudna identifies delivery into the patient's body as a core bottleneck and the next development path for turning CRISPR from ex-vivo procedures into broader therapeutics.

←

▶ 13:27 · $CRISPR · Doudna says in-vivo delivery is the next unlock for CRISPR therapies

now playing · $CRISPR

$CRISPR···bullish· mediumjennifer doudna

Doudna says the CRISPR startup ecosystem has already spun out 31 companies worth $9B

The investment signal is not a single ticker but the scale of the CRISPR commercialization pipeline: dozens of companies, thousands of jobs, and continued progress toward real-wor…

$OPENAIbearish· mediumjennifer doudna

Jennifer Doudna pushes back on OpenAI-style claims that chatbots will own drug discovery

Doudna says AI can help summarize data and improve discovery efficiency, but she does not see chatbots inventing new drug ideas or justifying a claim on future drug sales today.

$CRISPR···bullish· mediumjennifer doudna

Doudna says in-vivo delivery is the next unlock for CRISPR therapies

Doudna identifies delivery into the patient's body as a core bottleneck and the next development path for turning CRISPR from ex-vivo procedures into broader therapeutics.